New drugs are being tested for the treatment of Multiple Myeloma to find the least toxic and most potent one.
Let's talk about how these drugs act.
Mezigdomide, a Cereblon E3 ubiquitin ligase modulator, targets Ikaros and CK1α inhibiting tumor growth.
We need to know more about:
to know about Mezigdomide.
There is a recent study of mezigdomide plus dexamethasone in multiple myeloma patients.primary objectives were to evaluate the safety and efficacy of mezigdomide plus dexamethasone .
results were promising
ck1a
Regulates signaling pathways related to
membrane trafficking,
cell cycle progression,
chromosome segregation,
apoptosis,
autophagy,
cell metabolism,
differentiation in development,
circadian rhythm(first kinase to have this activity), immune response
neurodegeneration
cancer